Search results for " MYCN"
showing 7 items of 7 documents
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2.
2018
Pharmacologically difficult targets, such as MYC transcription factors, represent a major challenge in cancer therapy. For the childhood cancer neuroblastoma, amplification of the oncogene MYCN is associated with high-risk disease and poor prognosis. Here, we deployed genome-scale CRISPR-Cas9 screening of MYCN-amplified neuroblastoma and found a preferential dependency on genes encoding the polycomb repressive complex 2 (PRC2) components EZH2, EED, and SUZ12. Genetic and pharmacological suppression of EZH2 inhibited neuroblastoma growth in vitro and in vivo. Moreover, compared with neuroblastomas without MYCN amplification, MYCN-amplified neuroblastomas expressed higher levels of EZH2. ChIP…
Expresión inmunohistoquímica de la proteína mycN y el estado del gen MYCN en tumores neuroblásticos
2007
Antecedentes: Los tumores neuroblásticos son de los tumores pediátricos más frecuentes. A pesar de su gran variedad genética, clínica e histopatológica, la amplificación del gen MYCN es siempre un indicador de mal pronóstico. Este oncogen codifica una proteína nuclear que se une al ADN y activa la transcripción de sus genes diana. Un aumento en el número de copias del gen no se corresponde siempre con sobreexpresión de su proteína. El valor pronóstico de la detección de la proteína es controvertido. Métodos: Se han analizado 220 muestras de NB. Mediante la técnica de FISH se ha establecido el estado del gen, mientras que la inmunohistoquímica ha permitido el estudio de la expresión de la pr…
Zvaigžņotā Debess: 2005, Vasara
2005
Contents: In memoriam Arturs Balklavs-Grīnhofs ; Parting Words to Arturs Balklavs ; List of Publications by Prof. Dr.phys. Arturs Balklavs-Grīnhofs ; Astronomy in 25 Years of Soviet Latvia ; Man in Space: Based on newspaper “Pravda” materials ; U.Dzērvītis. Centenary of the Theory of Relativity ; A.Balklavs. Gamma Emission from the Galactic Centre ; A.Alksnis, Z.Alksne. Fewer Brown Dwarfs, More Red Ones ; A.Alksnis. New Observations of the Eruptive Variable Star V838 Mon ; A.Balklavs. Cosmic Objects in Captivating Photos – 5 ; J. Freimanis. On Polarization of Continuous Solar Spectrum ; J.Jaunbergs. The Very First Contact with Titan ; A.Millers. Biological Effects of Cosmic Rays ; J.Jansons…
Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes
2021
Survival in high-risk neuroblastoma (HR-NB) patients remains poor despite multimodal treatment. We aimed to identify HR-NB patients with worse outcomes by analyzing the genomic instability derived from segmental chromosomal aberrations. We calculated 3 genomic instability indexes for primary tumor SNP array profiles from 127 HR-NB patients: (1) Copy number aberration burden (%gainslength+%losseslength), (2) copy number load (CNL) (%gainslength-%losseslength) and (3) net genomic load (NGL) (%gainsamount-%lossesamount). Tumors were classified according to positive or negative CNL and NGL genomic subtypes. The impact of the genomic instability indexes on overall survival (OS) was assessed with…
Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration
2014
AbstractNeuroblastoma (NB) is a common malignancy in children but rarely occurs during adolescence or adulthood. This subgroup is characterized by an indolent disease course, almost uniformly fatal, yet little is known about the biologic characteristics. The aim of this study was to identify differential features regarding DNA copy number alterations, α-thalassemia/mental retardation syndrome X-linked (ATRX) protein expression, and the presence of tumor-associated inflammatory cells. Thirty-one NB patients older than 10 years who were included in the Spanish NB Registry were considered for the current study; seven young and middle-aged adult patients (range 18-60 years) formed part of the c…
Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.
2009
The Italian Neuroblastoma Registry was investigated to describe 781 children with neuroblastoma experiencing tumour recurrence (424 progressions and 357 relapses). Ten-year overall survival (OS) was 6.8% (95% confidence interval (CI) 4.3-10.0) after progression and 14.4% (95% CI 10.5-18.9) after relapse. For both circumstances, OS was better for age at diagnosis <18 months, less advanced International Neuroblastoma Staging System (INSS) stage, normal lactate dehydrogenase (LDH) serum level, normal MYCN gene status (P<0.001) and a non-abdominal primary site (P=0.034 for progression, and P=0.004 for relapses). A local type of recurrence had a significantly better outcome only in case of relap…
Patología de los tumores neuroblásticos: evaluación pronóstica. Experiencia del centro español de referencia de la SEOP para estudios biopatológicos …
2007
Antecedentes: Los tumores neuroblásticos son los tumores sólidos extracraneales más frecuentes en la infancia y se caracterizan por una evolución clínica heterogénea que va desde una progresión rápida a una regresión tumoral espontánea. Existen factores pronósticos conocidos que determinan dicha evolución como son la edad, estadiaje, histopatología, estatus de MYCN, ploidía y diversas ganancias y pérdidas cromosómicas. El objetivo del trabajo es describir nuestra experiencia como laboratorio de referencia español para la determinación de estos parámetros pronósticos. Métodos: Material tumoral de pacientes con neuroblastoma, remitido a nuestro laboratorio desde 1992 hasta 2005, ha sido somet…